Merck Sinemet (Slow-Release)

Description

Active Ingredient: This medication is composed of a combination of two ingredients Levodopa and Carbidopa. Levodopa is an amino acid that shows antiparkinsonian properties. It is a prodrug that is converted to dopamine by DOPA decarboxylase, which can cross the blood-brain barrier. It stimulates the dopaminergic receptors to compensate for the depleted supply of endogenous dopamine occurred in Parkinson’s disease. For assurance for the adequate concentrations of it reach the central nervous system, it is taken with carbidopa. Carbidopa is a decarboxylase inhibitor that is unable to cross the blood-brain barrier to diminish the decarboxylation and inactivation of levodopa in peripheral tissues.

Indications: Given effective drugs is a combination of active ingredients approved for the treatment of symptoms of Parkinson’s disease or Parkinson-like symptoms for instance shakiness, stiffness, or difficulty moving. Parkinson’s disease caused by a naturally occurring substance like dopamine in the brain. Levodopa ingredient in Sinemet CR changes into dopamine in the brain that controls movement. Carbidopa component prevents the breakdown of another ingredient in the bloodstream so as to enter the brain. This component can also reduce some of levodopa’s side effects includes nausea and vomiting.

Action Mechanism: This mentioned medication is a polymeric-based drug that controls the release of carbidopa and levodopa as it slowly erodes. It is available to facilitate titration when required.

Dosages: This medication a combination of two drugs is available for oral administration. Sinemet CR is available in a dosage as follows:

• 100 mg + 25 mg: It should be consumed with or without food as directed by the doctor, usually 2 to 3 times a day

Note: It is advisable to consume this medication with food, it may help to decrease nausea.